Trial Outcomes & Findings for MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas (NCT NCT02311582)

Last Updated: 2025-05-29

Results Overview

The MTD is defined as the dose level immediately below the dose level at which 2 patients of a cohort (of 2 to 6 patients) experienced dose-limiting toxicity during the first cycle. Dose escalations will proceed until the MTD has been reached, or failing that, 200 mg of MK-3475 every 3 weeks will be considered the MTD.

Recruitment status

COMPLETED

Study phase

PHASE1/PHASE2

Target enrollment

55 participants

Primary outcome timeframe

Completion of Cycle 1 (each cycle is 3 weeks)

Results posted on

2025-05-29

Participant Flow

Participant milestones

Participant milestones
Measure	Phase I: MK-3475 + MLA Dose Level 1 MK-3475 will be given at 100 mg intravenously (IV) every 3 weeks starting no more than 1 week after MLA until progression or unacceptable toxicity.	Phase I: MK-3475 + MLA Dose Level 2 MK-3475 will be given at 150 mg intravenously (IV) every 3 weeks starting no more than 1 week after MLA until progression or unacceptable toxicity.	Phase I: MK-3475 + MLA Dose Level 3 MK-3475 will be given at 200 mg intravenously (IV) every 3 weeks starting no more than 1 week after MLA until progression or unacceptable toxicity.	Phase II: MK-3475 + MLA MK-3475 will be given at 200 mg intravenously (IV) every 3 weeks no more than 1 week after MLA, or no more than 1 week after biopsy (if no surgical debulking). This dose was determined in the Phase I portion of the trial.	Phase II: MK-3475 Only MK-3475 will be given at 200 mg intravenously (IV) every 3 weeks beginning 3 weeks after surgical debulking or no more than 1 week after biopsy (if no surgical debulking). This dose was determined in the Phase I portion of the trial.
Overall Study STARTED	3	3	3	36	10
Overall Study COMPLETED	3	3	3	30	6
Overall Study NOT COMPLETED	0	0	0	6	4

Reasons for withdrawal

Reasons for withdrawal
Measure	Phase I: MK-3475 + MLA Dose Level 1 MK-3475 will be given at 100 mg intravenously (IV) every 3 weeks starting no more than 1 week after MLA until progression or unacceptable toxicity.	Phase I: MK-3475 + MLA Dose Level 2 MK-3475 will be given at 150 mg intravenously (IV) every 3 weeks starting no more than 1 week after MLA until progression or unacceptable toxicity.	Phase I: MK-3475 + MLA Dose Level 3 MK-3475 will be given at 200 mg intravenously (IV) every 3 weeks starting no more than 1 week after MLA until progression or unacceptable toxicity.	Phase II: MK-3475 + MLA MK-3475 will be given at 200 mg intravenously (IV) every 3 weeks no more than 1 week after MLA, or no more than 1 week after biopsy (if no surgical debulking). This dose was determined in the Phase I portion of the trial.	Phase II: MK-3475 Only MK-3475 will be given at 200 mg intravenously (IV) every 3 weeks beginning 3 weeks after surgical debulking or no more than 1 week after biopsy (if no surgical debulking). This dose was determined in the Phase I portion of the trial.
Overall Study Was enrolled but did not receive any MK-3475 treatment	0	0	0	6	4

Baseline Characteristics

MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Phase I: MK-3475 + MLA Dose Level 1 n=3 Participants MK-3475 will be given at 100 mg intravenously (IV) every 3 weeks starting no more than 1 week after MLA until progression or unacceptable toxicity.	Phase I: MK-3475 + MLA Dose Level 2 n=3 Participants MK-3475 will be given at 150 mg intravenously (IV) every 3 weeks starting no more than 1 week after MLA until progression or unacceptable toxicity.	Phase I: MK-3475 + MLA Dose Level 3 n=3 Participants MK-3475 will be given at 200 mg intravenously (IV) every 3 weeks starting no more than 1 week after MLA until progression or unacceptable toxicity.	Phase II: MK-3475 + MLA n=36 Participants MK-3475 will be given at 200 mg intravenously (IV) every 3 weeks no more than 1 week after MLA, or no more than 1 week after biopsy (if no surgical debulking). This dose was determined in the Phase I portion of the trial.	Phase II: MK-3475 Only n=10 Participants MK-3475 will be given at 200 mg intravenously (IV) every 3 weeks beginning 3 weeks after surgical debulking or no more than 1 week after biopsy (if no surgical debulking). This dose was determined in the Phase I portion of the trial.	Total n=55 Participants Total of all reporting groups
Age, Continuous	57 years n=5 Participants	41 years n=7 Participants	67 years n=5 Participants	60 years n=4 Participants	56.5 years n=21 Participants	57 years n=8 Participants
Sex: Female, Male Female	2 Participants n=5 Participants	1 Participants n=7 Participants	2 Participants n=5 Participants	19 Participants n=4 Participants	7 Participants n=21 Participants	31 Participants n=8 Participants
Sex: Female, Male Male	1 Participants n=5 Participants	2 Participants n=7 Participants	1 Participants n=5 Participants	17 Participants n=4 Participants	3 Participants n=21 Participants	24 Participants n=8 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	2 Participants n=5 Participants	3 Participants n=7 Participants	3 Participants n=5 Participants	36 Participants n=4 Participants	10 Participants n=21 Participants	54 Participants n=8 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	1 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	1 Participants n=8 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants
Race (NIH/OMB) Asian	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	1 Participants n=4 Participants	0 Participants n=21 Participants	1 Participants n=8 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants
Race (NIH/OMB) Black or African American	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	1 Participants n=4 Participants	0 Participants n=21 Participants	1 Participants n=8 Participants
Race (NIH/OMB) White	3 Participants n=5 Participants	3 Participants n=7 Participants	3 Participants n=5 Participants	34 Participants n=4 Participants	10 Participants n=21 Participants	53 Participants n=8 Participants
Race (NIH/OMB) More than one race	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants
Region of Enrollment United States	3 participants n=5 Participants	3 participants n=7 Participants	3 participants n=5 Participants	36 participants n=4 Participants	10 participants n=21 Participants	55 participants n=8 Participants

PRIMARY outcome

Timeframe: Completion of Cycle 1 (each cycle is 3 weeks)

Outcome measures

Outcome measures
Measure	Phase II: MK-3475 Only MK-3475 will be given at 200 mg intravenously (IV) every 3 weeks beginning 3 weeks after surgical debulking or no more than 1 week after biopsy (if no surgical debulking). This dose was determined in the Phase I portion of the trial.	Phase I MTD + Phase II: MK-3475 + MLA n=9 Participants MK-3475 will be given at 200 mg intravenously (IV) every 3 weeks no more than 1 week after MLA, or no more than 1 week after biopsy (if no surgical debulking). This dose was determined in the Phase I portion of the trial.	Phase II: MK-3475 Only MK-3475 will be given at 200 mg intravenously (IV) every 3 weeks beginning 3 weeks after surgical debulking or no more than 1 week after biopsy (if no surgical debulking). This dose was determined in the Phase I portion of the trial.	Phase I: MK-3475 + MLA Dose Level 3 MK-3475 will be given at 200 mg intravenously (IV) every 3 weeks starting no more than 1 week after MLA until progression or unacceptable toxicity.	Phase II: MK-3475 + MLA MK-3475 will be given at 200 mg intravenously (IV) every 3 weeks no more than 1 week after MLA, or no more than 1 week after biopsy (if no surgical debulking). This dose was determined in the Phase I portion of the trial.
Maximum Tolerated Dose (MTD) of MK-3475 When Combined With MLA - Phase I Only	—	200 mg	—	—	—

PRIMARY outcome

Timeframe: Through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).

Population: Participants are evaluable for this outcome measure if they were treated in the Phase II portion of the trial (includes Phase II MK-3475 + MLA and Phase II MK-3475 Only) and at the MTD in Phase I (MK-3475 + MLA Dose Level 3). The Phase I MTD is included with the Phase II MK-3475 + MLA arm since the patients received the same dosing of treatment.

PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first.

Outcome measures

Outcome measures
Measure	Phase II: MK-3475 Only MK-3475 will be given at 200 mg intravenously (IV) every 3 weeks beginning 3 weeks after surgical debulking or no more than 1 week after biopsy (if no surgical debulking). This dose was determined in the Phase I portion of the trial.	Phase I MTD + Phase II: MK-3475 + MLA n=33 Participants MK-3475 will be given at 200 mg intravenously (IV) every 3 weeks no more than 1 week after MLA, or no more than 1 week after biopsy (if no surgical debulking). This dose was determined in the Phase I portion of the trial.	Phase II: MK-3475 Only n=6 Participants MK-3475 will be given at 200 mg intravenously (IV) every 3 weeks beginning 3 weeks after surgical debulking or no more than 1 week after biopsy (if no surgical debulking). This dose was determined in the Phase I portion of the trial.	Phase I: MK-3475 + MLA Dose Level 3 MK-3475 will be given at 200 mg intravenously (IV) every 3 weeks starting no more than 1 week after MLA until progression or unacceptable toxicity.	Phase II: MK-3475 + MLA MK-3475 will be given at 200 mg intravenously (IV) every 3 weeks no more than 1 week after MLA, or no more than 1 week after biopsy (if no surgical debulking). This dose was determined in the Phase I portion of the trial.
Progression-free Survival (PFS) - Phase II Only	—	5.3 months Interval 3.4 to 12.4	2.1 months Interval 0.99 to The upper 95% confidence interval is not available as there is an insufficient number of participants with events.	—	—

SECONDARY outcome

Timeframe: Through 90 days after completion of treatment (up to 168 weeks)

Population: Participants in Phase II were not evaluable for this outcome measure.

* The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for all toxicity reporting * The only toxicities that will not be collected are those that are clearly related to MLA and/or surgery AND ALSO not related to MK-3475 * Adverse events will be tracked from start of treatment through 30 days following the last day of study treatment. Serious adverse events will be tracked for 90 days following the last dose of study treatment.

Outcome measures

Outcome measures
Measure	Phase II: MK-3475 Only MK-3475 will be given at 200 mg intravenously (IV) every 3 weeks beginning 3 weeks after surgical debulking or no more than 1 week after biopsy (if no surgical debulking). This dose was determined in the Phase I portion of the trial.	Phase I MTD + Phase II: MK-3475 + MLA n=3 Participants MK-3475 will be given at 200 mg intravenously (IV) every 3 weeks no more than 1 week after MLA, or no more than 1 week after biopsy (if no surgical debulking). This dose was determined in the Phase I portion of the trial.	Phase II: MK-3475 Only n=3 Participants MK-3475 will be given at 200 mg intravenously (IV) every 3 weeks beginning 3 weeks after surgical debulking or no more than 1 week after biopsy (if no surgical debulking). This dose was determined in the Phase I portion of the trial.	Phase I: MK-3475 + MLA Dose Level 3 n=3 Participants MK-3475 will be given at 200 mg intravenously (IV) every 3 weeks starting no more than 1 week after MLA until progression or unacceptable toxicity.	Phase II: MK-3475 + MLA MK-3475 will be given at 200 mg intravenously (IV) every 3 weeks no more than 1 week after MLA, or no more than 1 week after biopsy (if no surgical debulking). This dose was determined in the Phase I portion of the trial.
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 lethargy	—	1 Participants	1 Participants	0 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 anemia	—	1 Participants	1 Participants	1 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 3/4/5 lactic acidosis	—	0 Participants	0 Participants	1 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 3/4/5 leukocytosis	—	0 Participants	0 Participants	1 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 tachycardia	—	0 Participants	1 Participants	0 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 blurred vision	—	1 Participants	0 Participants	1 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 drooping eyes	—	0 Participants	0 Participants	1 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 floaters	—	1 Participants	0 Participants	0 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 glaucoma	—	0 Participants	0 Participants	1 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 pressure around eyes	—	0 Participants	0 Participants	1 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 right visual field cut	—	0 Participants	0 Participants	1 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 swollen eyes	—	0 Participants	0 Participants	1 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 3/4/5 abdominal pain	—	0 Participants	1 Participants	0 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 diarrhea	—	0 Participants	0 Participants	1 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 3/4/5 diarrhea	—	0 Participants	3 Participants	0 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 dysphagia	—	1 Participants	0 Participants	0 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 nausea	—	1 Participants	0 Participants	0 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 oral pain	—	0 Participants	0 Participants	1 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 rectal hemorrhage	—	0 Participants	0 Participants	1 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 vomiting	—	1 Participants	0 Participants	0 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 edema face	—	0 Participants	1 Participants	1 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 edema limbs	—	0 Participants	0 Participants	1 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 fatigue	—	1 Participants	2 Participants	1 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 fever	—	0 Participants	1 Participants	0 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 infusion related reaction	—	0 Participants	1 Participants	0 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 pain	—	0 Participants	0 Participants	1 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 3/4/5 appendicitis	—	1 Participants	0 Participants	0 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 bronchial infection	—	0 Participants	0 Participants	1 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 3/4/5 cellulitis	—	0 Participants	0 Participants	1 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 cold	—	0 Participants	1 Participants	0 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 pneumonia	—	1 Participants	0 Participants	0 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 3/4/5 sepsis	—	0 Participants	0 Participants	1 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 urinary tract infection	—	1 Participants	0 Participants	0 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 3/4/5 urinary tract infection	—	0 Participants	1 Participants	0 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 bruising	—	0 Participants	1 Participants	1 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 fall	—	0 Participants	1 Participants	2 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 3/4/5 fracture	—	0 Participants	0 Participants	1 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 wound from fall	—	0 Participants	0 Participants	1 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 alanine aminotransferase increased	—	0 Participants	1 Participants	0 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 alkaline phosphatase increased	—	0 Participants	1 Participants	0 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 blood bilirubin increased	—	0 Participants	0 Participants	1 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 creatinine increased	—	1 Participants	0 Participants	1 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 lymphocyte count decreased	—	0 Participants	3 Participants	2 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 platelet count decreased	—	2 Participants	0 Participants	1 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 weight loss	—	0 Participants	0 Participants	1 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 white blood cell decreased	—	2 Participants	1 Participants	0 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 hyperglycemia	—	3 Participants	1 Participants	0 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 3/4/5 hyperglycemia	—	0 Participants	0 Participants	1 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 hyperkalemia	—	0 Participants	0 Participants	1 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 hypernatremia	—	0 Participants	0 Participants	1 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 hypoalbuminemia	—	0 Participants	1 Participants	0 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 hyponatremia	—	0 Participants	0 Participants	1 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 arthritis	—	0 Participants	0 Participants	1 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 back pain	—	0 Participants	1 Participants	1 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 chest wall pain	—	0 Participants	1 Participants	0 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 dystonia	—	0 Participants	1 Participants	0 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 generalized muscle weakness	—	0 Participants	0 Participants	1 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 joint effusion	—	1 Participants	0 Participants	0 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 muscle weakness - left sided	—	1 Participants	1 Participants	0 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 muscle weakness - right sided	—	0 Participants	1 Participants	0 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 3/4/5 muscle weakness - right sided	—	0 Participants	0 Participants	1 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 muscle weakness - upper limb	—	0 Participants	0 Participants	1 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 pain in extremity	—	0 Participants	1 Participants	0 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 3/4/5 altered mental status	—	0 Participants	1 Participants	0 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 cognitive disturbance	—	1 Participants	0 Participants	0 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 dizziness	—	1 Participants	1 Participants	1 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 edema cerebral	—	0 Participants	1 Participants	0 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 expressive aphasia	—	0 Participants	1 Participants	0 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 lightheadedness	—	1 Participants	0 Participants	0 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 memory impairment	—	0 Participants	0 Participants	1 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 3/4/5 peripheral motor neuropathy	—	0 Participants	1 Participants	0 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 reading comprehension difficulty	—	1 Participants	0 Participants	0 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 3/4/5 seizure	—	1 Participants	1 Participants	0 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 3/4/5 speech aphasia	—	0 Participants	0 Participants	1 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 word-finding difficulty	—	1 Participants	0 Participants	0 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 agitation	—	0 Participants	1 Participants	0 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 anxiety	—	1 Participants	0 Participants	1 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 confusion	—	0 Participants	0 Participants	1 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 insomnia	—	0 Participants	1 Participants	0 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 hematuria	—	0 Participants	0 Participants	2 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 urinary incontinence	—	0 Participants	0 Participants	1 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 cough	—	1 Participants	1 Participants	1 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 dyspnea	—	1 Participants	0 Participants	1 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 nasal congestion	—	0 Participants	1 Participants	0 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 dry skin	—	0 Participants	1 Participants	1 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 hyperhidrosis	—	0 Participants	0 Participants	1 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 3/4/5 rash	—	0 Participants	1 Participants	0 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 3/4/5 skin ulceration	—	0 Participants	1 Participants	0 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 3/4/5 planned left craniectomy	—	0 Participants	0 Participants	1 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 hot flashes	—	1 Participants	0 Participants	1 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 hypertension	—	0 Participants	0 Participants	1 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 3/4/5 hypotension	—	1 Participants	0 Participants	0 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 3/4/5 pulmonary embolism	—	0 Participants	1 Participants	0 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 1/2 headache	—	1 Participants	1 Participants	2 Participants	—
Toxicity Profile of MK-3475 in Combination With MLA - Phase I Only Grade 3/4/5 intracranial hemorrhage	—	0 Participants	0 Participants	1 Participants	—

SECONDARY outcome

Timeframe: Through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).

OS is defined as the duration of time from start of treatment to time of death.

Outcome measures

Outcome measures
Measure	Phase II: MK-3475 Only MK-3475 will be given at 200 mg intravenously (IV) every 3 weeks beginning 3 weeks after surgical debulking or no more than 1 week after biopsy (if no surgical debulking). This dose was determined in the Phase I portion of the trial.	Phase I MTD + Phase II: MK-3475 + MLA n=33 Participants MK-3475 will be given at 200 mg intravenously (IV) every 3 weeks no more than 1 week after MLA, or no more than 1 week after biopsy (if no surgical debulking). This dose was determined in the Phase I portion of the trial.	Phase II: MK-3475 Only n=6 Participants MK-3475 will be given at 200 mg intravenously (IV) every 3 weeks beginning 3 weeks after surgical debulking or no more than 1 week after biopsy (if no surgical debulking). This dose was determined in the Phase I portion of the trial.	Phase I: MK-3475 + MLA Dose Level 3 MK-3475 will be given at 200 mg intravenously (IV) every 3 weeks starting no more than 1 week after MLA until progression or unacceptable toxicity.	Phase II: MK-3475 + MLA MK-3475 will be given at 200 mg intravenously (IV) every 3 weeks no more than 1 week after MLA, or no more than 1 week after biopsy (if no surgical debulking). This dose was determined in the Phase I portion of the trial.
Overall Survival (OS) - Phase II Only	—	11.8 months Interval 8.9 to 27.7	5.2 months Interval 1.7 to The upper 95% confidence interval is not available as there is an insufficient number of participants with events.	—	—

SECONDARY outcome

Timeframe: Up to 26 months

Population: Patients underwent pre-LITT surgery or biopsy concurrent with LITT with resulting tissue (no minimum tissue volume requirement) first determining eligibility \& any remaining tissue made available for the analyses listed in the secondary outcome measures. In practice, concurrent local biopsy was heavily favored over two stage surgeries for study participants. Biopsy provided comparatively smaller volumes of tissue \&, unfortunately ended up not providing adequate tissue for this analysis.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 6 months

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Up to 2 years after completion of treatment (estimated to be up to 272 weeks)

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Up to 2 years after completion of treatment (estimated to be up to 272 weeks)

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Up to 2 years after completion of treatment (estimated to be up to 272 weeks)

Outcome measures

Outcome data not reported

Adverse Events

Phase I: MK-3475 + MLA Dose Level 1

Serious events: 3 serious events

Other events: 3 other events

Deaths: 3 deaths

Phase I: MK-3475 + MLA Dose Level 2

Serious events: 2 serious events

Other events: 3 other events

Deaths: 2 deaths

Phase I: MK-3475 + MLA Dose Level 3

Serious events: 2 serious events

Other events: 3 other events

Deaths: 1 deaths

Phase II: MK-3475 + MLA

Serious events: 15 serious events

Other events: 30 other events

Deaths: 26 deaths

Phase II: MK-3475 Only

Serious events: 2 serious events

Other events: 6 other events

Deaths: 5 deaths

Serious adverse events

Serious adverse events
Measure	Phase I: MK-3475 + MLA Dose Level 1 n=3 participants at risk MK-3475 will be given at 100 mg intravenously (IV) every 3 weeks starting no more than 1 week after MLA until progression or unacceptable toxicity.	Phase I: MK-3475 + MLA Dose Level 2 n=3 participants at risk MK-3475 will be given at 150 mg intravenously (IV) every 3 weeks starting no more than 1 week after MLA until progression or unacceptable toxicity.	Phase I: MK-3475 + MLA Dose Level 3 n=3 participants at risk MK-3475 will be given at 200 mg intravenously (IV) every 3 weeks starting no more than 1 week after MLA until progression or unacceptable toxicity.	Phase II: MK-3475 + MLA n=30 participants at risk MK-3475 will be given at 200 mg intravenously (IV) every 3 weeks no more than 1 week after MLA, or no more than 1 week after biopsy (if no surgical debulking). This dose was determined in the Phase I portion of the trial.	Phase II: MK-3475 Only n=6 participants at risk MK-3475 will be given at 200 mg intravenously (IV) every 3 weeks beginning 3 weeks after surgical debulking or no more than 1 week after biopsy (if no surgical debulking). This dose was determined in the Phase I portion of the trial.
Blood and lymphatic system disorders Lactic acidosis	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Cardiac disorders Tachycardia	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Gastrointestinal disorders Abdominal pain	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Gastrointestinal disorders Dysphagia	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Gastrointestinal disorders Nausea	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Gastrointestinal disorders Vomiting	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
General disorders Fever	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
General disorders Lethargy	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Infections and infestations Appendicitis	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Infections and infestations Cellulitis	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Infections and infestations Herpes zoster infection	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Infections and infestations Rash maculo-papular	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Infections and infestations Sepsis	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Infections and infestations Sinusitis	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Infections and infestations Urinary tract infection	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Injury, poisoning and procedural complications Fall	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Injury, poisoning and procedural complications Prolonged hospitalization following MLA	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Injury, poisoning and procedural complications Spinal compression fracture	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Injury, poisoning and procedural complications Wound dehiscence	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Metabolism and nutrition disorders Hyponatremia	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Musculoskeletal and connective tissue disorders Generalized muscle weakness	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Musculoskeletal and connective tissue disorders Muscle weakness left-sided	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Musculoskeletal and connective tissue disorders Muscle weakness lower limb	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Musculoskeletal and connective tissue disorders Muscle weakness right-sided	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	16.7% 1/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Recurrent glioblastoma	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	16.7% 1/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Nervous system disorders Ataxia	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Nervous system disorders Cerebral edema	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Nervous system disorders Dysarthria	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	16.7% 1/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Nervous system disorders Dysphasia	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	6.7% 2/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Nervous system disorders Headache	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Nervous system disorders Intracranial hemorrhage	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	16.7% 1/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Nervous system disorders Left-sided weakness	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Nervous system disorders Right-sided weakness	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Nervous system disorders Seizure	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	66.7% 2/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	13.3% 4/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Nervous system disorders Speech aphasia	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Psychiatric disorders Altered mental status	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	16.7% 1/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Psychiatric disorders Confusion	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	6.7% 2/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	16.7% 1/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Respiratory, thoracic and mediastinal disorders Dyspnea	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Respiratory, thoracic and mediastinal disorders Nasal congestion	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Respiratory, thoracic and mediastinal disorders Productive cough	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Skin and subcutaneous tissue disorders Rash	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Surgical and medical procedures Planned left craniectomy	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Surgical and medical procedures Planned post-progression Monteris Laser Ablation procedure	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Surgical and medical procedures Planned post-progression surgical resection	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Surgical and medical procedures Ventriculoperitoneal shunt placement	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	16.7% 1/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Vascular disorders Hypotension	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Vascular disorders Pulmonary embolism	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).

Other adverse events

Other adverse events
Measure	Phase I: MK-3475 + MLA Dose Level 1 n=3 participants at risk MK-3475 will be given at 100 mg intravenously (IV) every 3 weeks starting no more than 1 week after MLA until progression or unacceptable toxicity.	Phase I: MK-3475 + MLA Dose Level 2 n=3 participants at risk MK-3475 will be given at 150 mg intravenously (IV) every 3 weeks starting no more than 1 week after MLA until progression or unacceptable toxicity.	Phase I: MK-3475 + MLA Dose Level 3 n=3 participants at risk MK-3475 will be given at 200 mg intravenously (IV) every 3 weeks starting no more than 1 week after MLA until progression or unacceptable toxicity.	Phase II: MK-3475 + MLA n=30 participants at risk MK-3475 will be given at 200 mg intravenously (IV) every 3 weeks no more than 1 week after MLA, or no more than 1 week after biopsy (if no surgical debulking). This dose was determined in the Phase I portion of the trial.	Phase II: MK-3475 Only n=6 participants at risk MK-3475 will be given at 200 mg intravenously (IV) every 3 weeks beginning 3 weeks after surgical debulking or no more than 1 week after biopsy (if no surgical debulking). This dose was determined in the Phase I portion of the trial.
Blood and lymphatic system disorders Anemia	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	20.0% 6/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Blood and lymphatic system disorders Leukocytosis	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Cardiac disorders Atrial fibrillation	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Cardiac disorders Sinus tachycardia	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Ear and labyrinth disorders Balance issues	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Ear and labyrinth disorders Ear pain	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Ear and labyrinth disorders Tinnitus	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Endocrine disorders Hyperthyroidism	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	16.7% 5/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	16.7% 1/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Endocrine disorders Hypothyroidism	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Eye disorders Blurred vision	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	10.0% 3/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Eye disorders Drooping eyes	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Eye disorders Floaters	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Eye disorders Glaucoma	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Eye disorders Pressure around eyes	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Eye disorders Right eye visual disturbance	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	16.7% 1/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Eye disorders Right peripheral field deficit	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	16.7% 1/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Eye disorders Right visual field cut	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Eye disorders Swollen eyes	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Eye disorders Vision changes	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	6.7% 2/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Eye disorders Worsening right visual field cut	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	16.7% 1/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Gastrointestinal disorders Abdominal distension	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	16.7% 1/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Gastrointestinal disorders Abdominal pain	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Gastrointestinal disorders Constipation	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	6.7% 2/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Gastrointestinal disorders Diarrhea	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	100.0% 3/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	26.7% 8/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 2/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Gastrointestinal disorders Dyspepsia	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Gastrointestinal disorders Dysphagia	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	6.7% 2/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Gastrointestinal disorders Fecal incontinence	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	10.0% 3/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Gastrointestinal disorders Gastroesophageal reflux	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	10.0% 3/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Gastrointestinal disorders Mucositis oral	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	6.7% 2/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Gastrointestinal disorders Nausea	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	20.0% 6/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	16.7% 1/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Gastrointestinal disorders Oral pain	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Gastrointestinal disorders Rectal hemorrhage	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	16.7% 1/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Gastrointestinal disorders Stomach pain	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	6.7% 2/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Gastrointestinal disorders Vomiting	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	6.7% 2/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 2/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
General disorders Chills	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
General disorders Edema	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	16.7% 1/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
General disorders Edema face	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	10.0% 3/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	16.7% 1/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
General disorders Edema limbs	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	13.3% 4/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
General disorders Fatigue	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	66.7% 2/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	53.3% 16/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	50.0% 3/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
General disorders Fever	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	6.7% 2/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
General disorders Fluid collection from elbow	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
General disorders Infusion related reaction	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
General disorders Left shoulder pain	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
General disorders Malaise	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
General disorders Pain	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	20.0% 6/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	16.7% 1/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Infections and infestations Bronchial infection	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Infections and infestations COVID-19 infection	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Infections and infestations Cold	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Infections and infestations Herpes zoster	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Infections and infestations Mucosal - Thrush	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Infections and infestations Nail infection	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Infections and infestations Pneumonia	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Infections and infestations Sinusitis	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	6.7% 2/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Infections and infestations Skin infection	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Infections and infestations Upper respiratory infection	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Infections and infestations Urinary tract infection	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Injury, poisoning and procedural complications Bruising	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	6.7% 2/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Injury, poisoning and procedural complications Fall	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	66.7% 2/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	16.7% 5/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Injury, poisoning and procedural complications Fracture	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Injury, poisoning and procedural complications Post-operative aphasia	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	16.7% 1/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Injury, poisoning and procedural complications Wound - finger laceration	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Injury, poisoning and procedural complications Wound from fall	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Investigations Activated thromboplastin time prolonged	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Investigations Alanine aminotransferase increased	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	16.7% 5/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 2/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Investigations Alkaline phosphatase increased	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Investigations Aspartate aminotransferase increased	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Investigations Blood bilirubin increased	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Investigations Creatinine increased	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	6.7% 2/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Investigations Hemoglobin increased	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Investigations INR increased	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Investigations Lymphocyte count decreased	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	100.0% 3/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	66.7% 2/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	73.3% 22/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	83.3% 5/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Investigations Neutrophil count decreased	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	6.7% 2/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Investigations Platelet count decreased	66.7% 2/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	13.3% 4/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	50.0% 3/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Investigations Weight gain	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	20.0% 6/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	16.7% 1/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Investigations Weight loss	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	6.7% 2/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Investigations White blood cell decreased	66.7% 2/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	16.7% 5/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 2/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Metabolism and nutrition disorders Anorexia	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	23.3% 7/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Metabolism and nutrition disorders Dehydration	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Metabolism and nutrition disorders Hypercalcemia	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	16.7% 1/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Metabolism and nutrition disorders Hyperglycemia	100.0% 3/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	13.3% 4/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	50.0% 3/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Metabolism and nutrition disorders Hyperkalemia	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Metabolism and nutrition disorders Hypernatremia	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	6.7% 2/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Metabolism and nutrition disorders Hypoalbuminemia	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	10.0% 3/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Metabolism and nutrition disorders Hypocalcemia	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 2/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Metabolism and nutrition disorders Hypoglycemia	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	6.7% 2/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Metabolism and nutrition disorders Hypokalemia	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	10.0% 3/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Metabolism and nutrition disorders Hyponatremia	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	16.7% 5/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Metabolism and nutrition disorders Hypophosphatemia	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	16.7% 1/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Musculoskeletal and connective tissue disorders Arthralgia	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	13.3% 4/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Musculoskeletal and connective tissue disorders Arthritis	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Musculoskeletal and connective tissue disorders Back pain	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	6.7% 2/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Musculoskeletal and connective tissue disorders Chest wall pain	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Nervous system disorders Neuralgia	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Musculoskeletal and connective tissue disorders Dystonia	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Musculoskeletal and connective tissue disorders Exostosis	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Musculoskeletal and connective tissue disorders Generalized muscle weakness	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	10.0% 3/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Musculoskeletal and connective tissue disorders Joint effusion	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Musculoskeletal and connective tissue disorders Muscle weakness left-sided	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	13.3% 4/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	16.7% 1/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Musculoskeletal and connective tissue disorders Muscle weakness lower limb	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	6.7% 2/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Musculoskeletal and connective tissue disorders Muscle weakness right-sided	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Musculoskeletal and connective tissue disorders Myalgia	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	6.7% 2/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Musculoskeletal and connective tissue disorders Neck pain	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Musculoskeletal and connective tissue disorders Pain in extremity	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Musculoskeletal and connective tissue disorders Upper limb muscle weakness	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Nervous system disorders Aphasia	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 2/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Nervous system disorders Cognitive disturbance	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	16.7% 5/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Nervous system disorders Concentration impairment	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Nervous system disorders Dizziness	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	16.7% 5/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Nervous system disorders Dysgeusia	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Nervous system disorders Dysphasia	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	23.3% 7/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	16.7% 1/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Nervous system disorders Edema cerebral	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	6.7% 2/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Nervous system disorders Expressive aphasia	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Nervous system disorders Gait disturbance	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	10.0% 3/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Nervous system disorders Headache	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	66.7% 2/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	40.0% 12/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	83.3% 5/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Nervous system disorders Hemiparesis	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Nervous system disorders Hydrocephalus	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	16.7% 1/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Nervous system disorders Intracranial hemorrhage	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Nervous system disorders Irritability	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Nervous system disorders Lethargy	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Nervous system disorders Lightheadedness	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Nervous system disorders Memory impairment	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	10.0% 3/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 2/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Nervous system disorders Paresthesia	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	16.7% 5/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Nervous system disorders Peripheral motor neuropathy	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	6.7% 2/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Nervous system disorders Peripheral sensory neuropathy	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	16.7% 1/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Nervous system disorders Pseduomeningocele	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 2/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Nervous system disorders Reading comprehension difficulty	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Nervous system disorders Seizure	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	6.7% 2/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 2/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Nervous system disorders Somnolence	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Nervous system disorders Speech and coordination	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	16.7% 1/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Nervous system disorders Tremor	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	13.3% 4/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Nervous system disorders Word-finding difficulty	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 2/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Nervous system disorders Worsening speech	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	16.7% 1/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Psychiatric disorders Agitation	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	6.7% 2/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Psychiatric disorders Albulia	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Psychiatric disorders Anxiety	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	16.7% 5/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	16.7% 1/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Psychiatric disorders Confusion	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	30.0% 9/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Psychiatric disorders Depression	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	20.0% 6/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Psychiatric disorders Euphoria	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Psychiatric disorders Hallucinations	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	6.7% 2/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Psychiatric disorders Insomnia	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	20.0% 6/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Psychiatric disorders Irritability	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 2/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Renal and urinary disorders Hematuria	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	66.7% 2/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Renal and urinary disorders Urinary frequency	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	6.7% 2/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Renal and urinary disorders Urinary incontinence	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	6.7% 2/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Reproductive system and breast disorders Erectile dysfunction	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Respiratory, thoracic and mediastinal disorders Anosmia	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Respiratory, thoracic and mediastinal disorders Cough	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	16.7% 5/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Respiratory, thoracic and mediastinal disorders Dyspnea	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	10.0% 3/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	16.7% 1/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Respiratory, thoracic and mediastinal disorders Nasal congestion	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	6.7% 2/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Respiratory, thoracic and mediastinal disorders Nasal mucositis	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Respiratory, thoracic and mediastinal disorders Productive cough	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Respiratory, thoracic and mediastinal disorders Sore throat	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Skin and subcutaneous tissue disorders Acne on face	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Skin and subcutaneous tissue disorders Alopecia	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Skin and subcutaneous tissue disorders Blisters from herpes zoster infection	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Skin and subcutaneous tissue disorders Dry skin	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Skin and subcutaneous tissue disorders Hyperhidrosis	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Skin and subcutaneous tissue disorders Intertriginous dermatitis	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Skin and subcutaneous tissue disorders Papulopustular rash	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Skin and subcutaneous tissue disorders Pruritus	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	10.0% 3/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 2/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Skin and subcutaneous tissue disorders Rash acneiform	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Skin and subcutaneous tissue disorders Redness on scalp due to Optune device	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Skin and subcutaneous tissue disorders Redness on upper back	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Skin and subcutaneous tissue disorders Skin irritation from Optune device	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	6.7% 2/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Skin and subcutaneous tissue disorders Skin ulceration	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Vascular disorders Hot flashes	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	3.3% 1/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Vascular disorders Hypertension	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	60.0% 18/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).
Vascular disorders Thromboembolic event	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	33.3% 1/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/3 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	6.7% 2/30 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).	0.00% 0/6 • Adverse events were followed from start of MK-3475 through 30 days following the last day of treatment (median length of follow-up 152 days, full range 43-1778 days). Serious adverse events were followed from start of MK-3475 through 90 days following the last day of treatment (median length of follow-up 212 days, full range 43-1838 days). All-cause mortality was followed from start of MK-3475 through completion of follow-up (median length of follow-up 338 days, full range 43-2468 days).

Additional Information

Milan G. Chheda, M.D.

Washington University School of Medicine

Phone: 314-747-2712

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place